AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Cell Division Cycle 7 (CDC7) Related Protein Kinase Inhibitor - Pipeline Insight, 2019 Featuring Lin Bioscience, Takeda Oncology, and Nerviano Medical Sciences - ResearchAndMarkets.com

February 22, 2019

DUBLIN--(BUSINESS WIRE)--Feb 22, 2019--The “Cell Division Cycle 7 (CDC7) Related Protein Kinase Inhibitor - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Cell Division Cycle 7 (CDC7) Related Protein Kinase Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cell Division Cycle 7 (CDC7) Related Protein Kinase Inhibitor development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

Reasons to Buy

Companies Mentioned

Topics Covered

1. Report Introduction

2. Cell Division Cycle 7 (CDC7) Related Protein Kinase Inhibitor - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Cell Division Cycle 7 (CDC7) Related Protein Kinase Inhibitor Pipeline Products in Clinical Stages

6. Cell Division Cycle 7 (CDC7) Related Protein Kinase Inhibitor Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment: Active Products

8. Inactive Pipeline Products

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/kpzkgl/cell_division?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190222005247/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs,Enzymes

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/22/2019 08:09 AM/DISC: 02/22/2019 08:09 AM

http://www.businesswire.com/news/home/20190222005247/en